Alexander Kuklin, Ph.D.
About Alexander Kuklin, Ph.D.
Alexander Kuklin, Ph.D., serves as the Vice President of CDx and BioPharma Partnerships at Predicine, where he has worked since 2021. He has extensive experience in the medical diagnostics and biotechnology sectors, having held various leadership roles at companies such as Roche Tissue Diagnostics and Guardant Health.
Current Role at Predicine
Alexander Kuklin, Ph.D. serves as the Vice President of CDx and BioPharma Partnerships at Predicine, a position he has held since 2021. In this role, he focuses on establishing and nurturing partnerships within the biopharmaceutical sector, leveraging his extensive background in companion diagnostics. His work involves strategic collaboration to enhance the development and implementation of diagnostic solutions.
Previous Experience in Diagnostics and Biotechnology
Kuklin has held various significant roles in the diagnostics and biotechnology industries. He was a Senior Manager of Business Development for Companion Diagnostics at Roche Tissue Diagnostics from 2010 to 2014. He also worked as a Director of Business Development for Pharma Services and CDx at OncoPlex Diagnostics in 2014. His career includes positions at Guardant Health, Leica Biosystems, and Immunicon Corporation, where he contributed to business development and strategic sales initiatives.
Education and Expertise
Kuklin earned his Ph.D. in Molecular Biology from the University of Tennessee, Knoxville, between 1991 and 1995. He also completed a certificate in Strategy Execution from Harvard Business School Online in 2021. His educational background, combined with his extensive experience, equips him with a strong foundation in both scientific and business aspects of the diagnostics field.
Achievements in FDA Approvals
Throughout his career, Kuklin has been involved in the FDA approval process for several companion diagnostics. Notably, he was part of the team that achieved FDA accelerated approval for the VENTANA PD-L1 (SP263) Assay for urothelial carcinoma. He also contributed to the approval of the Guardant360 CDx for non-small cell lung cancer, demonstrating his impact on advancing diagnostic solutions in oncology.
International Sales Management Experience
Kuklin has extensive experience in international sales management, having collaborated with partners across Europe, Asia, and Australia. His ability to leverage company resources effectively has resulted in significant revenue growth. He possesses a strong capability to present technical solutions in an understandable manner, which aids in creating urgency for clients in the medical diagnostics sector.